---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-032453"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2024-08-15T23:59:59+00:00"
generated_at: "2026-05-31T09:02:36.051262+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vivos Therapeutics Q2 revenue up 19% YoY to $4.1M; operating expenses down 31%

## Summary
- Revenue $4.1M vs $3.4M YoY; gross margin improved to 65% from 62%.
- Operating loss reduced 57% YoY; eight straight quarters of YoY expense cuts.
- Cash $6.9M; stockholders' equity $6.3M; expects positive cash flow in early 2025.
- Received Medicare reimbursement for CARE oral devices; closed $7.5M equity investment from New Seneca Partners.
- New strategic alliance with sleep testing centers in Colorado; pilot showed 79% of patients chose Vivos therapy over CPAP.

## SEC filing metadata
- accession: 0001493152-24-032453
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2024-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000149315224032453/0001493152-24-032453-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000149315224032453/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-032453
- JSON: https://secwatch.observer/filing/0001493152-24-032453.json
- Plain text: https://secwatch.observer/filing/0001493152-24-032453.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.